FundLens

Best Pharma & Healthcare Funds

Defensive-growth exposure to pharma, hospitals and diagnostics.

Data updated · 19 direct-growth funds ranked by a transparent 0–100 Smart Score

19
Funds
2
Strong Buys
Very High
Risk
19 funds
⚖Want to compare funds? Tick the checkbox in the first column — pick up to 5 and they'll go head-to-head in one view.
⚖ VSFund Score ↓Verdict1Y 3Y 5Y Sharpe Sortino Std Dev Alpha Beta VR★ P/E Expense AUM Age
SBI Healthcare Opportunities
SBI
82
Strong Buy26.1%24.6%20.7%1.231.9514.45.30.83—58.11.00%₹6.1k Cr13.9y
HDFC Pharma And Healthcare
HDFC
79
Strong Buy31.6%30.6%—1.402.4016.28.90.91—49.51.04%₹3.7k Cr3.1y
Mirae Asset Healthcare
Mirae Asset
73
Buy28.1%23.7%17.8%1.091.7116.03.40.93—48.70.61%₹3.6k Cr8.5y
Kotak Healthcare
Kotak
72
Buy33.1%——1.171.6714.614.80.68—51.41.03%₹859 Cr2.9y
UTI Healthcare
UTI
59
Hold22.0%23.1%17.7%1.061.7116.03.50.90—40.31.34%₹1.4k Cr13.9y
DSP Healthcare
DSP
58
Hold19.1%20.6%16.9%1.011.5415.13.20.80—36.20.75%₹3.7k Cr8.0y
ICICI Pru Healthcare
ICICI Pru
54
Hold10.6%21.6%18.3%0.99—16.22.40.91——1.30%₹7.1k Cr8.4y
WhiteOak Capital Pharma And Heathcare
WhiteOak
52
Hold26.2%————————51.81.07%₹964 Cr2.8y
PGIM India Healthcare
PGIM India
50
Hold26.4%——0.590.8213.310.00.64—50.30.98%₹142 Cr2.0y
Bajaj Finserv Healthcare
Bajaj Finserv
45
Hold24.2%——0.410.5713.76.10.68—48.10.90%₹419 Cr1.9y
ABSL Pharma And Healthcare
Aditya Birla Sun Life
41
Avoid19.4%19.9%15.9%0.971.4915.41.40.90—48.31.05%₹1.1k Cr7.4y
Tata India Pharma & Healthcare
Tata
40
Avoid10.7%18.4%15.8%0.891.2613.47.80.62—40.61.09%₹1.5k Cr10.9y
Nippon India Pharma
Nippon India
39
Avoid14.1%17.8%15.2%0.851.2213.17.30.59—38.60.99%₹9.1k Cr13.9y
Invesco India Pharma and Healthcare
Invesco
34
Avoid—————————67.3—₹474 Cr0.2y
Baroda BNP Paribas Health And Wellness
Baroda BNP Paribas
33
Avoid16.0%——0.180.2612.04.40.57—44.71.47%₹478 Cr1.4y
LIC MF Healthcare
LIC
31
Avoid18.3%21.4%14.8%0.991.4916.22.60.89—53.61.38%₹97 Cr7.7y
ITI Pharma And Healthcare
ITI
28
Avoid17.1%19.9%15.6%0.871.2916.50.30.94—48.30.89%₹267 Cr5.0y
Bandhan Healthcare
Bandhan
25
Avoid—————————39.11.25%₹325 Cr1.0y
Quant Healthcare
Quant
23
Avoid19.9%20.1%—0.851.0818.22.30.88—28.11.62%₹416 Cr3.4y
Reading the ratios: ↑ higher is better — Returns, Sharpe, Sortino, Alpha · ↓ lower is better — Std Dev, P/E, Expense · Beta ≈1 moves with the market (<1 swings less). Hover any column header for details.

Pharma & Healthcare funds — quick answers

›Which is the best Pharma & Healthcare mutual fund right now?

SBI Healthcare Opportunities currently ranks #1 of 19 Pharma & Healthcare funds with a FundLens Smart Score of 82/100 (Strong Buy). It returned 24.6% over 3 years and 20.7% over 5 years at a 1.00% expense ratio (direct plan). Rankings are recomputed from data updated 20 Nov 2026.

›Which Pharma & Healthcare fund has the best risk-adjusted returns?

HDFC Pharma And Healthcare leads the category on the Sortino ratio at 2.40 (Sharpe 1.40) — meaning it has delivered the most return per unit of downside risk among Pharma & Healthcare funds.

›Which Pharma & Healthcare fund has the lowest expense ratio?

Mirae Asset Healthcare charges 0.61% a year (direct plan) — the lowest in the category. Lower fees compound in your favour over long holding periods.

›Which is the smallest Pharma & Healthcare fund by AUM?

LIC MF Healthcare manages ₹97 Cr, the smallest in the category. Smaller funds can be nimbler, but check track record and costs before treating size alone as an edge.

›How long should I stay invested in a Pharma & Healthcare fund?

Pharma & Healthcare funds carry very high risk, so a horizon of 7+ years is generally sensible. Defensive-growth exposure to pharma, hospitals and diagnostics. This is research, not investment advice.

Want these answers conversationally? Ask FundLens · New to the ratios? Sharpe vs Sortino, explained